Forecasting and Monitoring Budgetary impact and medicines uptake
|
|
- Gregory Fitzgerald
- 5 years ago
- Views:
Transcription
1 Forecasting and Monitoring Budgetary impact and medicines uptake Kate Jenkins and Paul Deslandes Welsh Analytical Prescribing Support Unit All Wales Therapeutics and Toxicology Centre
2 WAPSU Remit Medicines management projects Wales Patient Access Schemes Financial forecasting for new medicines Prescribing monitoring and analysis
3 Introduction Estimating budget impact of medicines in the AWMSG work program Budget impact of medicine uptake post ratification Monitoring usage (in Wales) of medicines appraised by AWMSG and NICE Correlating predicted vs observed expenditure
4 Budget impact
5 In an ideal world (At least) two years before positive appraisal recommendation: Implementation date Estimated number of patients Estimated cost Estimated place in treatment Service delivery costs (resource use)
6 Background Financial forecasting added to the WAPSU work-plan by Welsh Government in 2013 Forecasting focus group meeting held in Abergavenny in July 2013 Forecasting group established autumn 2013 and includes: Pharmacist, and finance representatives Members from each health board, NWIS and Welsh Government Forecasting group met for the first time in December 2013 with subsequent meetings on a quarterly basis
7 Role of WAPSU and forecasting group Collate data from budget impact section of AWMSG ASAR documents Produce a rolling quarterly report Report reviewed by the group at each meeting Individual members feedback to relevant colleagues at their health board An interactive budget impact calculator is in development (in pilot phase)
8 Budget impact software Initially focussed on AWMSG appraisals, to provide: Estimate of direct drug cost using list price Estimate of net change in direct drug cost vs comparator Default values for the above using estimates from the ASAR Ability to input predicted local level usage (to account for variation in disease prevalence, prescriber interest etc) Ability to input local drug unit cost (to account for PAS and other local price variation)
9 What do we need? Budget impact information presented in a consistent way Consider: Patients eligible: prevalence, incidence, applicable population Patients treated: estimated uptake, discontinuers, cumulative numbers CIC information
10 Remit to produce an annual report analysing the use of medicines which have undergone appraisal by either NICE or AWMSG.
11 Limitations with the data
12 April 2003 March 2015 NICE TAs currently active 150 AWMSG Number appraisals medicines 0 Negative recommendation Positive recommendation Statement of Advice
13 Top 20 - Recommended
14 Inositol nicotinate Bosutinib Aflibercept concentrate for infusion Amantadine hydrochloride Paricalcitol Eribulin Ruxolitinib Fulvestrant Sorafenib Bevacizumab Ofatumumab Micafungin Fampridine Insulin degludec Olanzapine depot injection Bromfenac Pentoxyfylline Cilostazol Racecadotril granules for suspension Aliskiren Cabazitaxel Dasatinib M
15 Use of the newer oral anticoagulants is increasing 700, , ,000 Spend ( ) 400, , , ,000 0 Apixaban Dabigatran Rivaroxaban Warfarin
16 Oral anticoagulants Total NHS Wales spend on NOACs for the financial year was 3.6 million: a 158% increase in spend over the previous year. Rivaroxaban made up the majority (53%), perhaps because of its broader range of indications, dabigatran etexilate makes up 27% and apixaban 19% of total spend NOACs make up 5.2% of anticoagulant items prescribed in primary care Variation across Wales 1.78 to 6.93 items/1,000 PUs (average 4.2 items/1,000 PUs) NOACs make up 10.5% of anticoagulant items in primary care in England, average 6.06 items/1,000 PUs
17 Long-acting muscarinic antagonists Tiotropium was the first inhaled LAMA to be available in the UK In the last three years, three new inhaled LAMAs have been launched and received a positive recommendation from AWMSG. Spend on tiotropium by NHS Wales for was 15.9 million Spend on the three newer LAMAs for the same period was 538,000 (3% of all LAMA spend) Also need to consider the new LAMA/LABA combination inhalers Spend ( ) 120, ,000 80,000 60,000 40,000 20,000 0 Aclidinium bromide Glycopyrronium Umeclidinium
18 Actual versus estimated Medicine Ratification date Company estimate patients Company estimate cost Observed cost % of estimated cost Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 1 Glycopyrronium bromide 22/5/ ,270 30, , ,917 99, % Aclidinium bromide 31/7/ ,220 3, , ,904 1,203, ,844 56% Umeclidinium 9/1/15 1,289 2,611 3, , ,685 1,329,280
19 Analogue insulin Three analogue insulins currently available in the UK Approximately 97% of insulin spend is in primary care Analogue insulin accounts for 91% of long- and intermediate- acting insulin items issued in primary care ( 8.5 million for the financial year ) Although majority of use is in primary care, influenced heavily by specialists in secondary care Spend ( ) 1,800,000 1,600,000 1,400,000 1,200,000 1,000, , , , ,000 0 Area of potential interest in light of: new NICE guideline licensing of biosimilar insulins Insulin degludec Insulin glargine Insulin detemir Isophane insulin
20 Thank you Diolch yn Fawr
MONITORING OF MEDICINES APPRAISED BY NICE AND AWMSG SUMMARY
MONITORING OF MEDICINES APPRAISED BY NICE AND AWMSG SUMMARY April 2014 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics and Toxicology
More informationMonitoring Usage in Wales of Medicines Appraised by NICE and AWMSG
Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG November 2015 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics
More informationMonitoring Usage in Wales of Medicines Appraised by NICE and AWMSG
Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG November 2016 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics
More informationProcess for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015
Introduction Process for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015 From September 2015 the All Wales Medicines Strategy
More informationSmoking in Pregnancy. Policy Context. Chris Tudor-Smith Health Improvement Division Welsh Government
Smoking in Pregnancy Policy Context Chris Tudor-Smith Health Improvement Division Welsh Government Harms from smoking remain In Wales: Causes around 5,450 deaths each year in 35 year olds and over Major
More informationCosting Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)
Putting NICE guidance into practice Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Published: June 2014 This costing report accompanies the clinical
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Type 2 diabetes: the management of type 2 diabetes (update)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Type 2 diabetes: the management of type 2 diabetes (update) 1.1 Short title Type 2 diabetes (update) 2 Background a) The National
More informationPRESCRIBING INCENTIVE SCHEME 2018/19
PRESCRIBING INCENTIVE SCHEME 2018/19 Summary Harrogate and Rural District CCG is continuing to offer a prescribing incentive scheme to all its member NHS GP practices as encouragement and reward to improve
More informationMedicines Management Programme Update
Medicines Management Programme Update Sarah Clarke Chief II Pharmacist and Programme Manager Medicines Management Programme (MMP) www.hse.ie/yourmedicines Millions ( ) The Medicines Management Programme
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationNATIONAL PRESCRIBING INDICATORS ANALYSIS OF PRESCRIBING DATA: DECEMBER April 2013
NATIONAL PRESCRIBING INDICATORS 2012 2013 ANALYSIS OF PRESCRIBING DATA: DECEMBER 2012 April 2013 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationThe first stop for professional medicines advice. Community Pharmacy Oral Anticoagulant Safety Audit
Community Pharmacy Oral Anticoagulant Safety Audit This audit has been developed with help and support from the following organisations: Community Pharmacy Patient Safety Group PharmOutcomes Pharmaceutical
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationNational Prescribing Indicators Annual Primary Care Prescribing Report
National Prescribing Indicators 214 215 Annual Primary Care Prescribing Report This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder. Reference number: 938 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder Reference number: 938 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Glycopyrronium bromide (Seebri Breezhaler ) 44 micrograms inhalation powder as hard capsules
AWMSG SECRETARIAT ASSESSMENT REPORT Glycopyrronium bromide (Seebri Breezhaler ) 44 micrograms inhalation powder as hard capsules Reference number: 1455 FULL SUBMISSION This report has been prepared by
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationAHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke. Version: 13 March 2017
AHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke Version: 13 March 2017 Introduction This business case template has been created so that
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationNational Prescribing Indicators Supporting Information for Prescribers
National Prescribing Indicators 2018 2019 Supporting Information for Prescribers February 2018 This report has been prepared by a multiprofessional collaborative group, with support from the All Wales
More informationTackling atrial fibrillation the health economics evidence
Tackling atrial fibrillation the health economics evidence Professor Gary Ford,CBE Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford University Hospitals
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA151 Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus This guidance was issued in
More informationShort-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
More informationResource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430
Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option
More informationCosting statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS)
Putting NICE guidance into practice Costing statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS) Published: September
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More informationrequesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group
October 2015 Our Ref: FOI.15.ASH0149 requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group Original Request Survey attached. Question 1: Between 1 July 2014 and
More informationCalgary Long Term Care Formulary
Page 1 of 10 Calgary Long Term Care Formulary Pharmacy & Therapeutics November 2018 Highlights https://www.albertahealthservices.ca/info/page4071.aspx Page 2 of 10 Contents November 2018... 3 Formulary
More informationCalgary Long Term Care Formulary
Page 1 of 14 Calgary Long Term Care Formulary Pharmacy & Therapeutics Highlights https://www.albertahealthservices.ca/info/page4071.aspx Page 2 of 14 Contents... 3 Formulary Changes (Additions, Changes,
More informationNorth of Tyne Area Prescribing Committee DECISION SUMMARY North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
National Institute for Health and Clinical Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial Response
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic fatigue syndrome/myalgic encephalomyelitis: diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis in
More informationMinutes. 21 st July 2015, 12:30-2:30 pm Pharmacy Dept. CMFT
Minutes 21 st July 2015, 12:30-2:30 pm Pharmacy Dept. CMFT Present: Elizabeth Adcock (formerly Craig) (EA) Medicines Information Pharmacist, PAHT Jennifer Bartlett (JB) Senior Medicines Management Pharmacist
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Thank you for agreeing to give us a statement on your organisation s view of the technology and the way
More informationNHS WALES PRIMARY CARE PRESCRIBING ANALYSIS FOR TRAMADOL DATA TO SEPTEMBER 2014
NHS WALES PRIMARY CARE PRESCRIBING ANALYSIS FOR TRAMADOL DATA TO SEPTEMBER 2014 March 2015 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales
More informationGlobal Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017
Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021) April 2017 Global Anticoagulants Market Scope of the Report The report entitled Global Anticoagulants Market: Size, Trends & Forecasts
More informationCosting statement: chronic idiopathic constipation - Lubiprostone
Putting NICE guidance into practice Costing statement: chronic idiopathic constipation - Lubiprostone Implementing the NICE guidance on Lubiprostone for treating chronic idiopathic constipation (TA318)
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE HELEN WILLIAMS FFRPS, MRPHARMS, PGDIP (CARDIOL) IPRESC CONSULTANT PHARMACIST FOR CVD, SOUTH LONDON CLINICAL LEAD FOR ATRIAL FIBRILLATION, HEALTH INNOVATION
More informationQIPP Prescribing Comparators: Description and Specification
Prescribing s: Description and Specification This document details the descriptions and specifications for the prescribing comparators. They should be read in conjunction with the National Prescribing
More informationPharmaceutical System in the UK
Pharmaceutical System in the UK David Kullman Medicines, i Pharmacy and Industry Group Department of Health PPRI Conference, Vienna 30 September 2011 Disclaimer Conflict of interest: Nothing to disclose
More informationNORTH WALES NHS TRUST GLAN CLWYD HOSPITAL (CENTRAL AREA)
NORTH WALES NHS TRUST GLAN CLWYD HOSPITAL (CENTRAL AREA) MINUTES OF THE CONWY & DENBIGHSHIRE DRUG & THERAPEUTICS COMMITTEE MEETING HELD IN THE RON & MARGARET SMITH SEMINAR ROOM, NORTH WALES CANCER TREATMENT
More informationThat the Single Commissioning Board supports the project outlined in this report and proceeds as described.
Report to: SINGLE COMMISSIONING BOARD Date: 26 September 2017 Officer of Single Commissioning Board Subject: Report Summary: Recommendations: Jessica Williams Interim Director of Commissioning ATRIAL FIBRILLATION
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationALL WALES PRESCRIBING ADVISORY GROUP
Enclosure No: 5/AWMSG/1114 Agenda Item No: 9 Minutes of AWPAG Meeting 24 th September 2014 Author: Chairman, AWPAG Contact: Tel: 029 20716900 E-Mail: awttc@wales.nhs.uk ALL WALES PRESCRIBING ADVISORY GROUP
More informationManagement of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Continuous subcutaneous insulin infusion for the treatment of diabetes (review) Final scope Appraisal objective To review
More informationPriorities Advisory Committee
Insulin degludec (Tresiba ) PAC - Insulin degludec (Tresiba ) 2.1 The East of England Priorities Advisory Committee A function of GUIDANCE STATEMENT PAC Recommendations 1. Insulin degludec is NOT recommended
More informationInsulin detemir (Levemir)... 2 Leuprorelin... 4 Levetiracetam (Keppra)... 5 Budesonide/eformoteral (Symbicort) widening access...
August 2005 PTAC Meeting PTAC minutes are published in accordance with the following definitions from the PTAC Guidelines 2002: Minute means that part of the record of a PTAC or Sub-committee meeting (including
More informationThe Sustainability of Irish Pharmaceutical Expenditure. Valerie Walshe Ph.D. Economist
The Sustainability of Irish Pharmaceutical Expenditure Valerie Walshe Ph.D. Economist valerie.walshe@hse.ie February 2015 Content Overview of Irish Health Services Community Drug Prescribing Trends Driving
More informationMinutes. 19 th May 2015, 12:30-2:30 pm Pharmacy Dept. CMFT
Present: Minutes 19 th May 2015, 12:30-2:30 pm Pharmacy Dept. CMFT Elizabeth Adcock (formerly Craig) (EA) Medicines Information Pharmacist, PAHT Elizabeth Arkell (EA), Associate Director of Pharmacy, UHSM
More informationMedicines Management Programme Update
The Medicines Management Programme (MMP) Medicines Management Programme Update Michael Barry Clinical Lead HSE-Medicines Management Programme (MMP) www.hse.ie/yourmedicines What are our values? Ensuring
More informationPHARMAC responds on long-acting insulin analogues
Vol 118 No 1224 ISSN 1175 8716 PHARMAC responds on long-acting insulin analogues A Special Series article in August by Dr Jeremy Krebs discussed the timing of funding of long-acting insulin analogues in
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationHow many spoonfuls of sugar? A Bert s-eye view of prescribing to manage blood sugar
How many spoonfuls of sugar? A Bert s-eye view of prescribing to manage blood sugar What would Mary Poppins think? Please discuss Some Sums Annual cost of diabetes (1 &2) in England = c. 24 billion Around
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationGLORIA -AF REGISTRY PROGRAMME
GLORIA -AF REGISTRY PROGRAMME EXECUTIVE SUMMARY The approval of novel oral anticoagulants has changed prescribing patterns for stroke prevention in atrial fibrillation (AF) worldwide. 1 There is a need
More informationCOMMERCIAL BULLETIN. Inside this issue. Anticoagulants recommended over Aspirin
COMMERCIAL BULLETIN Monthly service July 2015 Anticoagulants recommended over Aspirin Patients who suffer from atrial fibrillation (AF) should be prescribed Anticoagulants and not Aspirin says National
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationEvidence Review for Prescribing Clinical Network
Summary page Evidence Review for Prescribing Clinical Network Treatment: LABA/LAMA Combination devices in COPD Anoro Ellipta, Ultibro and Duaklir Genuair Prepared by: Noreen Devanney Topic Submitted by:
More informationALL WALES MEDICINES STRATEGY GROUP (AWMSG)
Enclosure No: Agenda Item No: Author: Contact: 1/AWMSG/1214 4 Minutes of previous meeting Chairman, AWMSG Tel: 029 20716900 E-Mail: awttc@wales.nhs.uk ALL WALES MEDICINES STRATEGY GROUP (AWMSG) Draft minutes
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationNHS Diabetes Programme
NHS Diabetes Programme London Regional Event Vision Through the NHS Diabetes Programme we will aim to slow the future growth in the incidence of diabetes and reduce the rate of complications associated
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationTechnology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245
Apixaban for the prevention ention of venous thromboembolism after total hip or knee replacement in adults Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245 NICE 2018.
More informationThe clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years
The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the
More informationEdoxaban Switch Programme - Frequently Asked Questions
Edoxaban Switch Programme - Frequently Asked Questions What should I tell patients? NHS Tayside is reviewing all patients currently receiving a Direct Oral Anticoagulant (DOAC) for stroke prevention in
More informationNICE offer to STPs: CVD prevention
NICE offer to STPs: CVD prevention Zoe Girdis Regional Technical Adviser South of England and Channel Islands NICE support for STPs Based on the best available evidence of what works and is costeffective,
More informationMedicine Review (Adopted by the CCG until review and further notice) Medicine
East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast East Anglia Medicines Information Service Medicine Review (Adopted by the CCG until review
More informationPersonal statement on Continuous Subcutaneous Insulin Infusion Professor John Pickup
1 Personal statement on Continuous Subcutaneous Insulin Infusion Professor John Pickup King s College London School of Medicine, Guy s Hospital, London SE1 9RT Experience of the technology I am the lead
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us your views on the technology and the way it should be used in the NHS. Primary Care Trusts (PCTs) provide a unique perspective on the technology, which is not typically
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber At its last
More informationAn investigation into the effect of advice from the Scottish Medicines Consortium on the use of medicines in Scotland s Health Service
British Journal of Clinical Pharmacology DOI:1.1111/j.1365-2125.21.3826.x An investigation into the effect of advice from the Scottish Medicines Consortium on the use of medicines in Scotland s Health
More informationTitle Patients receiving dabigatran requiring emergency reversal for surgery or treatment of haemorrhage Guidelines. Department.
Document Control Title Patients receiving dabigatran requiring emergency reversal for surgery or treatment of haemorrhage Guidelines Author Author s job title Pharmacist Directorate PCS - Department Version
More informationNICE update. Paul Chrisp, Programme Director, Medicines and Prescribing Centre
NICE update Paul Chrisp, Programme Director, Medicines and Prescribing Centre Outline NICE offers a comprehensive suite of guidance, advice and support for delivering quality, safety and efficiency in
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review Review of TA151 Continuous subcutaneous insulin infusion for the treatment
More informationNetworking for success: A burning platform in Berkshire West
SERVICE REDESIGN CASE STUDY 1: NOVEMBER 2014 Networking for success: A burning platform in Berkshire West SUMMARY In 2012, four federated CCGs set up a network to redesign diabetes services in Berkshire
More informationAudit support for continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57)
Audit support for continuous subcutaneous insulin (review of technology appraisal guidance 57) Issue date: 2008 Audit support Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
More informationTools to manage the introduction of new drugs in Italy: administrative databases, registries and risk-sharing sharing schemes.
Tools to manage the introduction of new drugs in Italy: administrative databases, registries and risk-sharing sharing schemes. Roberta Joppi - Italian Horizon Scanning Project Local Health Unit of Verona
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationNovel oral anticoagulant therapy (NOAC)
Haematology Department Novel oral anticoagulant therapy (NOAC) Information for patients, relatives and carers What is novel oral anticoagulant therapy? Novel oral anticoagulants, or NOACs, are drugs which
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 10 July 2012 CONFIRMED MINUTES
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 10 July 2012 CONFIRMED MINUTES Summary Points Traffic lights Drug Rivaroxaban Dabigatran Drugs of Limited Clinical
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 10 February 2015 CONFIRMED MINUTES
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 10 February 2015 Summary Points CONFIRMED MINUTES Traffic lights Drug Calcium + Ergocalciferol (generic) Perindopril
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationrequesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group
requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14
More informationPutting NICE guidance into practice. Resource impact report: Hearing loss in adults: assessment and management (NG98)
Putting NICE guidance into practice Resource impact report: Hearing loss in adults: assessment and management (NG98) Published: June 2018 Summary This report focuses on the recommendation from NICE s guideline
More informationSurgery for Patients on Oral Anticoagulants
Surgery for Patients on Oral Anticoagulants (for example: warfarin, rivaroxaban, apixaban, dabigatran, edoxaban) Surgery Patient Information Leaflet You have been given this leaflet because you are due
More informationDouglas Dorward 5 th Year Medical Student, University of Dundee NCIN Cancer Outcomes Conference, Birmingham 14 th June 2012
Douglas Dorward 5 th Year Medical Student, University of Dundee NCIN Cancer Outcomes Conference, Birmingham 14 th June 2012 Professor John Dewar - Professor in Clinical Oncology Ninewells Hospital, Dundee
More informationAccess to newly licensed medicines. Scottish Medicines Consortium
Access to newly licensed medicines Scottish Medicines Consortium Modifiers The Committee has previously been provided with information about why the SMC uses modifiers in its appraisal process and also
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More information